eli lilly glp 1 pill The Food and Drug Administration has approved the first oral GLP-1 weight loss drug by Lilly, called Foundayo Eli Lilly Orforglipron Diabetes Trial

Description

Programs with active unresolved compliance issues or substantial unresolved consumer complaints were excluded from our top picks

Your Doctor May Prescribe a GLP-1 Drug If you've ever experienced a migraine, you know it's far more than just a bad headache

Women on skinny jabs must use effective contraception, MHRA urges in latest guidance

premier concerned about mammogram wait times as Opposition demands change02:09 | May 21, 2026 Tick researcher Nicoletta Faraone05:50 | May 21, 2026 WHO endorsement sparks new discussion around GLP-1 drugs and PCOS02:32 | December 14, 2025 Upwards of 12-hour waits for ER departments in Nova Scotia02:19 | July 16, 2026 New highly potent drug found amid overdose concerns in Maritimes02:18 | July 14, 2026 North End Community Health Centre Releases New Impact Report05:31 | July 14, 2026 Run With Rob Returns with His Biggest Challenge Yet05:52 | July 13, 2026 Importance of support and social services for home caregivers02:15 | July 9, 2026 Last One Standing & Summer Bash: Local Athletes Unite to Fight Brain Cancer05:41 | July 9, 2026 Virtual care promising quicker access amid health care challenges for Maritimers02:15 | July 3, 2026 Beach safety with Nova Scotia Lifeguard Service05:49 | July 3, 2026 How Maritimers are dealing with the scorching temperatures amid heat warning01:59 | July 2, 2026 Health Matters: ON, QC heat wave spreads to the Maritimes02:21 | July 2, 2026 Nova Scotian family raises money for rare genetic condition clinical trial02:21 | June 28, 2026 NS Accessibility Association launches new pilot in a unique way05:42 | June 25, 2026 Nova Scotia man turns speed walking into way to give back02:12 | June 22, 2026 Researchers raise concerns around social media bans02:09 | June 10, 2026 Paddling for a purpose: national campaign raises money for autism supports05:31 | June 10, 2026 African Nova Scotian advocates want expansion for community health program02:05 | June 9, 2026 Famillies relieved after tentative deal reached in striking LTC workers01:55 | June 8, 2026 New equine therapy program to help Nova Scotians with addictions recovery02:10 | June 7, 2026 Halifax-area man with MS speaks out about lack of accessibility02:15 | June 4, 2026 NS patients spread awareness of Spinal CSF Leaks02:12 | June 3, 2026 RBC Training Ground stops in Halifax01:55 | May 31, 2026 Family and community power Fredericton MS Walk01:50 | May 31, 2026 Nova Scotians challenging stigma of borderline personality disorder02:54 | May 30, 2026 Nova Scotia sexual assault survivor finds strength in being seen and heard02:56 | May 26, 2026 First responders, community feeling impact of newborn death in Halifax02:15 | May 26, 2026 Brianna Voss to Walk 200 Kilometres Across Nova Scotia for Huntington Disease Awareness and Support05:48 | May 26, 2026 MDC Walk & Roll champions Danny & Michelle Morris05:29 | May 26, 2026 Hundreds rally in N.S

Methods Study design Representatives of the companies Bristol-Myers Squibb, Novo Nordisk, Sanofi, Merck, Novartis, Boehringer Ingelheim and Takeda were contacted with the request to provide the event numbers of acute pancreatitis with the respective drug and non-incretin comparators as well as the corresponding number of patient-years of exposure (PYOs) for the approved GLP-1 receptor agonists exenatide twice daily, exenatide weekly, liraglutide and lixisenatide, as well as the DPP-4 inhibitors sitagliptin, saxagliptin, vildagliptin, alogliptin and linagliptin